FRM
PTCT icon

Fox Run Management’s PTC Therapeutics PTCT Stock Holding History

Fox Run Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,328
Closed -$651K – 1179
2025
Q2 		$651K Buy
+13,328
New +$633K 0.11% 353
2024
Q3 		– Sell
-27,997
Closed -$856K – 1046
2024
Q2 		$856K Buy
+27,997
New +$907K 0.16% 228
2024
Q1 		– Sell
-7,415
Closed -$204K – 1003
2023
Q4 		$204K Buy
+7,415
New +$170K 0.05% 629
2018
Q4 		– Sell
-11,017
Closed -$518K – 681
2018
Q3 		$518K Sell
11,017
-987
-8% -$40.8K 0.23% 166
2018
Q2 		$405K Buy
+12,004
New +$374K 0.13% 326

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fox Run Management's PTCT Position: Q3 2025 in Review

Fox Run Management sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 13,328 shares — an estimated $651K sold.

Fox Run Management first reported a position in PTCT in Q2 2018 and held it in 5 quarters. The position peaked at $856K in Q2 2024. 293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

  • Fox Run Management reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Fox Run Management sold 13,328 PTC Therapeutics shares in Q3 2025, an estimated $651K.
  • Fox Run Management first reported a position in PTC Therapeutics in Q2 2018 and held it in 5 quarters.
  • Fox Run Management's PTC Therapeutics position peaked at $856K in Q2 2024.
  • 293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Fox Run Management's 13F filing for Q3 2025, filed 12 Nov 2025.